A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
More Information
- Trial Status
- Not currently accepting
- Trial Phase
- Phase 1/2
- Enrollment
- 210 patients (estimated)
- Sponsors
- Cyclacel Pharmaceuticals, Inc.
- Tags
- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1499
- NCT Identifier
- NCT05168904
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.